Time for a Level Playing Field: Inequalities in Regulatory/Approval Processes—The Example of Bevacizumab in Epithelial Ovarian Cancer

open access

..... In summary, the decision to not approve bevacizumab in certain jurisdictions for ovarian cancer runs contrary to the evidence......Finally, harmful drugs, such as those with excessive and unmanageable adverse effects, should not be approved. However, this judgment needs to be made with the input of experts in the field: patients, their families, and practicing oncologists.